New York City data highlight the benefits of early administration of nirsevimab to safeguard infants from respiratory ...

The first study, published yesterday in Clinical Infectious Diseases, includes results of a phase 3 clinical trial (MELODY), ...

Use of nirsevimab was associated with an approximately 80% reduction in illness due to respiratory syncytial virus (RSV) ...

The drug, nirsevimab, was effective against respiratory syncytial virus infections when used in the Yukon-Kuskokwim Delta, a ...

The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...

Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab for infants demonstrate cost-effectiveness.

Thanks to research advances, two new effective prevention methods are now available. The first is nirsevimab, which is approved and recommended for infants 0–8 months old and select older ...

Nirsevimab (Beyfortus), an antibody targeting respiratory syncytial virus (RSV), is indicated for newborns and infants to prevent bronchiolitis. Available since September 2023, its widespread use ...

The drug, nirsevimab, was effective against respiratory syncytial virus infections when used in the Yukon-Kuskokwim Delta, a rural region known for high rates of that disease among infants ...

The researchers found that 45,693 outpatient visits, 15,866 emergency department visits, and 7571 hospitalizations among infants would be prevented each year by year-round maternal vaccination.

Seasonal maternal RSV vaccination may be cost-effective, particularly for those with higher risks. HealthDay News — Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab ...